The researchers found that when PCSK9 levels are low, pancreatic cancer cells are programmed to "scavenge" or consume nearby cholesterol from their immediate surroundings. Because the liver is naturally abundant in cholesterol, these low-PCSK9 cells find it to be an ideal environment for colonization. In this scenario, the cancer cells do not need to expend energy producing their own lipids; they simply absorb what is readily available in the hepatic tissue. This metabolic efficiency allows the tumor to establish itself quickly within the liver, often leading to the rapid progression of the disease in that organ.
However, the story changes when PCSK9 levels are high. In these instances, the cancer cells undergo a metabolic transformation. Instead of relying on external sources, high-PCSK9 cells begin to produce their own cholesterol internally. This self-sufficiency is a critical adaptation for survival in the lungs, where external cholesterol is scarce. Furthermore, the researchers discovered that the high levels of PCSK9 also trigger the production of specific molecules that protect the cancer cells from oxidative stress. Because the lungs are an environment defined by high oxygen exposure, cells are at constant risk of damage from reactive oxygen species. The metabolic shift orchestrated by PCSK9 provides a "perfect adaptation" for survival in the pulmonary environment, shielding the cancer cells from the very oxygen that sustains the rest of the body.
To test the strength of this discovery, the UCSF team conducted a series of experiments to see if they could manipulate the destination of the cancer. They took pancreatic cancer cells that were genetically predisposed to colonize the liver—cells that naturally expressed low levels of PCSK9—and forced them to express the protein at high levels. The results were striking. Instead of heading for the cholesterol-rich liver as they normally would, the modified cells made a literal and metaphorical detour, successfully colonizing the lungs instead. This confirmed that PCSK9 is not merely a marker of where a cell might go, but a primary driver of the metastatic process itself.
"Cancers persist by adapting to live in new tissues and organs, and we found that pancreatic tumors use PCSK9 to adapt as they spread," explained Dr. Perera. Her observations highlight a critical shift in cancer research: moving beyond looking at what a cancer cell is and focusing instead on what it does to survive in a new home. By identifying the metabolic tools these cells use to survive in hostile environments, researchers can begin to look for ways to take those tools away. "It opens the door to fighting metastatic cancer growth by manipulating how cells acquire their cholesterol," Perera added.
The implications of this study are profound for the future of pancreatic cancer treatment. Because pancreatic cancer is so often diagnosed only after it has reached the metastatic stage, understanding the mechanisms of spread is essential for developing therapies that can slow or stop the disease. If doctors can interfere with the PCSK9-driven metabolic switch, they might be able to prevent the cancer from adapting to new organs, or perhaps make the environments of the lungs and liver inhospitable to the invading cells.
